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Although information on efﬁcacy and adverse drugreactions
is lacking, ribavirin has been used empirically for the treat-
ment of severe acute respiratorysyndrome(SARS).Wereport
common adverse events in 110 patients with suspected or
probable SARS who were treated with ribavirin. Sixty-one
percent of the patients had evidence of hemolytic anemia,
and hypocalcemia and hypomagnesmiawerereportedin58%
and 46% of patients, respectively.
Severe acute respiratory syndrome (SARS) has affected 18000
people worldwide and has an estimated case-fatalityrateof5%–
19% [1]. In view of its broad-spectrum antiviral activity, treat-
ment with ribavirin was initiated empirically very early after
the recognition of the SARS outbreak.
Ribavirin is a synthetic nucleoside antiviral agent with in-
hibitory activity against both DNA and RNA viruses [2]. Ri-
bavirin, usually in an aerosolized form, has been used for the
treatment of respiratory syncytial virus pneumonitis in both
adults [3] and children [4]. The combination of oral ribavirin
and IFN has been shown to be efﬁcacious in the treatment of
chronic hepatitis C [5]. High-dose intravenous ribavirin has
been used in the treatment of Lassa fever and hemorrhagic
fever with renal syndrome [6, 7].
Despite the extensive recent use of ribavirin for thetreatment
of SARS, there has yet to be a detailed reportoutliningcommon
adverse events (AEs) temporally associated with the use of ri-
bavirin in this context. We describe the common AEs that were
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observed in a large Canadian cohort of patients with suspected
or probable SARS treated with ribavirin.
Methods. All patients with suspected or probable SARS
who were admitted to 5 hospitals in Toronto, Canada, were
reviewed for the development of possible AEs temporally as-
sociated with the initiation of ribavirin therapy. The following
common AEs that developed or worsened in association with
ribavirin treatment were identiﬁed: hemolytic anemia (HA; de-
crease in the hemoglobin level of 120 g/L plus 1 of thefollowing
events: an increase in the bilirubin level to 1.5 timesthebaseline
value, a haptoglobin level of !0.38 g/L, or a reticulocyte count
of 1110 reticuloyctes per 1000 erythrocytes), hypomagnesemia
(decrease from the baseline magnesium level to !0.7 mmol/L),
and hypocalcemia (decrease from the baseline calcium level to
!2.2 mmol/L, corrected for albumin). Other drugs used by
these patients included antibiotics (e.g., levoﬂoxacin or azith-
romycin, with or without ceftriaxone) and corticosteroids.
Risk factors associated with the development of each of the
AEs were compared using the x
2 test for categorical variables
and Student’s t test for continuous variables with a level of
signiﬁcance of . Data are shown as . P ! .05 mean SD
Results. A total of 110 patients with suspected or probable
SARS who were treated with ribavirin were identiﬁed from a
database compiled during phase 1 of a Canadian outbreak [8].
In view of thefactthat,earlyintheCanadianoutbreak,ribavirin
therapy was administered to patients who met the case deﬁ-
nition for suspected or probable SARS, an appropriate control
group of patients who had not received ribavirin was unavail-
able. The mean age of the patients was years(range, 45.7 17.2
17–99 years). There were 71 female patients and 39 male pa-
tients. All patients received concurrent antibiotics after the in-
itial assessment, and 50% received corticosteroidsatsomepoint
during the course of their illness.
A total of 67 patients (61%) had evidence of HA. Nineteen
(28%) of these patients received a transfusion of 1Uo f
packed RBCs. The decrease in the hemoglobin level was
g/L (range, 21–82 g/L). A signiﬁcant decrease (120 42.1 14.0
g/L) in the hemoglobin level was seen days after 6.8 2.7
starting ribavirin therapy, and the hemoglobin level reached a
nadir days after starting ribavirin therapy. HA was 13.0 4.1
signiﬁcantly associated with higher doses of ribavirin (P p
) and prolonged hospital stay ( ) (table 1). Neither .005 P p .001
age nor sex affected the development of HA.
Electrolyte data were available for a smaller cohort of pa-
tients. Thirty-ﬁve (46%) of these 76 patients developed hypo-
magnesemia while receiving therapy with ribavirin. Hypocal-
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Table 1. Clinical data for 110 patients with suspected or probable severe acute
respiratory syndrome who were treated with ribavirin.
Variable
Patients who
developed HA
(n p 67)
Patients with no
evidence of HA
(n p 43) P
Hemoglobin level, mean g/L   SD
Baseline 133.1   14.7 134.6   15.6 .62
Nadir 91.0   18.0 119.9   16.1 !.001
Treatment, no. (%) of patients
Corticosteroids
a 23 (51.1) 15 (48.3) .82
High-dose ribavirin
a,b 40 (88.9) 19 (61.3) .005
Length of hospital stay, mean days   SD 11.5   6.3 7.5   3.6 .001
NOTE. HA, hemolytic anemia.
a Data were available for only 76 patients.
b High-dose ribavirin therapy consisted of a cumulative dose of 20 g (e.g., 2 g iv as a loading
dose, followed by 1 g q6h for 4 days, then 500 mg q8h for 3 days); low-dose therapy consisted of a
cumulative dose of !20 g (e.g., 400 mg iv q8h for 4 days, followed by 1.2 g po b.i.d. for 7 days).
cemia was observed in 36 (58%) of 62 patients with corrected
calcium available. Twenty-two (29%) of 76 patients had evi-
dence of both hypocalcemia and hypomagnesemia. Although
most patientsremainedasymptomatic,1patientdevelopedgen-
eralized tetany, and another patient developed severe muscle
twitching and spasm of the face extending down the arms and
the upper chest that was believed to be due to the combination
of hypomagnesemia and hypocalcemia. The times to onset of
hypomagnesemia and hypocalcemia were and 4.15 1.9
days, respectively. Magnesium and calcium replace- 6.7 3.5
ment were initiated for 49% of patients with hypomagnesemia
and 47% of patients with hypocalcemia, respectively. Prophy-
lactic calcium and magnesium supplementation were not ef-
fective in preventing either. Hypomagnesemia, but not hypo-
calcemia, was signiﬁcantly associated with the dose of ribavirin,
and hypocalcemia was associated with a longer length of hos-
pital stay (table 2). Neither age nor sex contributed to the
development of hypocalcemia or hypomagnesemia.
Other AEs seen within the course of patients’ illness, such
as elevated transaminase levels, elevated lactate dehydrogenase
levels, elevated creatinine kinase levels, thrombocytopenia,and
lymphopenia, showed neither a clear dose-related effect nor a
clear time-related effect with ribavirin and were probably more
associated with the course of SARS illness (data not shown).
Discussion. Ribavirin is a broad-spectrum purine nucleo-
side analogue antiviral agent that has been empirically used in
the treatment of SARS. In contrast to the experience in the
Hong Kong outbreak, where ribavirin-associated AEs have not
been detailed in published retrospective and prospectivestudies
[9, 10], our experience with comparable doses of ribavirin sug-
gests that associated AEs occur frequently, have a dose-response
relationship, and correlate with a longer length of hospital stay.
The major established toxicity of ribavirin is reversible,dose-
dependent HA [11]. HA developed in 61% of our patients with
SARS who were treated with ribavirin and was signiﬁcantly
associated with the dose used (table 1). This is comparable to
the 58% incidence of HA associated withhigh-doseintravenous
ribavirin therapy for viral hemorrhagic fever syndromes [6],
but it is signiﬁcantly higher than the 7%–9% incidence associ-
ated with lower doses of oral ribavirin used for hepatitis C [11].
The nadir hemoglobin level occurred at day 13 after the start
of treatment, even after the completion of ribavirin therapy.
Also, not surprisingly, HA was associated with a prolonged
hospital stay.
Ribavirin-induced hemolytic anemia istypicallymanagedwith
reduction in the dosage or discontinuation of the ribavirin reg-
imen, but transfusion of packed RBCs is occasionally required
in cases of severe or symptomatic anemia. HA led to blood
transfusions in almost one-third of our patients. Erythropoietin
hasbeenusedinthetreatmentofanemiaassociatedwithribavirin
and IFN-a [12]. One of our patients received erythropoietin in
addition to a transfusion for treatment of HA.
Ribavirin-induced anemia may exacerbate cardiovascular
events in some patients [13]. It is recommended that caution
be exercised when starting ribavirin therapy for patients with
preexisting cardiovascular disease. No cardiovascular events
were observed in any of our ribavirin-treated patients.
Although the association between ribavirin and hypocal-
cemia has not been well established, it was noted in 9 of 20
patients receiving ribavirin plus consensus IFN and in only 2
of 20 patients receiving consensus IFN alone for chronic hep-
atitis C, suggesting that the decrease in the calcium level may
be, at least in part, related to ribavirin therapy [14]. Hypocal-
cemia has also been reported in 6 adult patients with severe
measles pneumonitis who were treated with ribavirin [15]; al-
though the hypocalcemia was attributed to disease, ribavirin
may have contributed to the development of this AE. Hypo-
magnesemia secondary to ribavirin use has not been previously
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Table 2. Clinical data associated with electrolyte disturbances in patients with sus-
pected or probable severe acute respiratory syndrome who were treated with ribavirin.
Variable
Patients who
developed
electrolyte
disturbance
Patients who had
no evidence of
electrolyte
disturbance P
Hypocalcemia
No. of patients (n p 62) 36 26
Calcium level, mean   SD
Baseline, mmol/L
a 2.26   0.13 2.25   0.14 .74
Percentage change 9.15   5.7 3.7   4.3 !.001
Treatment, no. (%) of patients
Calcium prophylaxis
b 9 (25.0) 6 (23.1) .86
Corticosteroids 22 (61.1) 10 (38.5) .08
High-dose ribavirin
c 27 (75) 18 (69) .62
Length of hospital stay, mean days   SD 12.2   7.2 6.6   3.9 .004
Hypomagnesemia
No. of patients (n p 76) 35 41
Magnesium level, mean   SD
Baseline, mmol/L 0.72   0.20 0.85   0.15 .008
Percentage change 36.0   13.4 3.4   25.2 !.001
Treatment, no. (%) of patients
Magnesium prophylaxis
d 11 (31.4) 13 (31.7) .98
Corticosteroids 16 (45.7) 22 (53.7) .49
High-dose ribavirin
c 34 (97.1) 25 (61.0) !.001
Length of hospital stay, mean days   SD 9.6   6.2 9.4   6.2 .89
a Corrected for albumin.
b Calcium carbonate (1250 mg t.i.d.) initiated at start of ribavirin therapy.
c High-dose ribavirin therapy consisted of a cumulative dose of 20 g (e.g., 2 g iv as a loading dose,
followed by 1 g q6h for 4 days, then 500 mg q8h for 3 days); low-dose therapy consisted of a cumulative
dose of !20 g (e.g., 400 mg iv q8h for 4 days, followed by 1.2 g po b.i.d. for 7 days).
d Magnesium glucoheptonate (30 mL b.i.d. [equivalent to 12 mmol/L per day]) initiated at the start of
ribavirin therapy.
described. A large proportion of our patients developed hypo-
calcemia (58%) and/or hypomagnesemia (46%) within the ﬁrst
week after initiation of ribavirin. Baseline hypocalcemia was
seen in 33% of patients; in contrast, only 10% of patients had
baseline hypomagnesemia. This implies that ribavirin may be
unmasking or accentuating what is, at least in part, a disease-
related effect. Neither calcium nor magnesium prophylactic
supplementation reduced the development of hypocalcemia
and/or hypomagnesemia.
Ribavirin has a signiﬁcant teratogenic and mutagenic effect.
Animal studies have demonstrated various congenital malfor-
mations, as well as growth retardation and fetal deaths. In ad-
dition, because of possible accumulation of ribavirin in sper-
matozoa, the concerns of mutagenic effects in the offspring of
men treated with ribavirin, and the unknown risk for terato-
genic effects of ribavirin in humans, strict contraceptive mea-
sures must be taken by both men and women treated with
ribavirin, both during treatment and for several months after
cessation [16]. The extensive accumulation of ribavirinnucleo-
tides and their slow dephosphorylation contribute to the long
half-life (∼300 h) after receipt of multiple doses. To prevent
potential teratogenic effects, it is recommended that 15 half-
lives (or 6 months) is required to ensure complete washout
after discontinuation of ribavirin [17].
Serious AEs, including HA and electrolyte disturbances, oc-
curred early and frequently in Canadian patients with SARS
who were treated with ribavirin. Ascribing causality in this
situation is difﬁcult in view of the lack of a comparably ill
control group not treated with ribavirin, the likelycontribution
of the underlying disease, the long intracellular half-life of ri-
bavirin, and the lack of rechallenge information. Health au-
thorities in Canada have restricted the use of ribavirin on the
basis of a lack of in vitro antiviral effect against SARS corona-
virus at therapeutic concentrations [18] and the high incidence
of ribavirin-associated AEs in treated patients [19]. A recent
retrospective Canadian study highlights that ribavirin may not
have clinical efﬁcacy, may actually adversely affect outcome,
and may need to be prematurely discontinued because of AEs
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in almost 20% of patients [20]. However, widespread use of
ribavirin continues in Hong Kong, where AEs comparable to
the Canadian experience have not been reported and where
continued use has been justiﬁed by the potential nonspeciﬁc
immunomodulatory activity of the drug and in vivo activity in
the mouse hepatitis coronavirus model [10]. In view of the
long half-life of ribavirin, the potential for teratogenicity, and
the potential for signiﬁcant drug-associated morbidity and
mortality, vigilant monitoring for both short-term and long-
term AEs is needed for patients exposed to this drug. The
Canadian experience with ribavirin in the treatment of SARS
suggests that the beneﬁts of use may not outweigh the risk of
AEs and the potential for ribavirin to have negative economic
consequences on hospitals endorsing its use.
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